Of particular note, the SGLT2 inhibitor group was younger (mean age 58 vs. 69 years; P < 0.0001), had a longer duration of diabetes (mean 7 vs. 5 years; P < 0.0001), were heavier (mean body weight 78 vs. 61 kg), and included a greater proportion of outpatients at baseline (93% vs. 74%; Table S2). This evidence concerns the gene SLC5A2 and diabetes mellitus.